Evidence map›Paper›PMID 40427609›Full record

ReviewBiomolecules2025

CXCR Family and Hematologic Malignancies in the Bone Marrow Microenvironment.

Yanquan Liu, Huanwen Tang

Abstract readReview
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yanquan LiuDepartment of Hematology, The First Dongguan Affiliated Hospital of Guangdong Medical University, The First School of Clinical Medicine, Guangdong Medical University, Dongguan 523808, China.ORCID 0000-0001-6826-0456
Huanwen TangDepartment of Hematology, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan Key Laboratory of Environmental Medicine, School of Public Health, Guangdong Medical University, Dongguan 523808, China.ORCID 0000-0003-1632-2103

Funding

Guangdong Basic and Applied Basic Research Foundation 2023A1515140169Guangdong Provincial University Key Platform Featured Innovation Project 2020KTSCX048National Natural Science Foundation of China 82073582, 82103876
6 · The paper itself

Abstract

Malignant hematologic diseases, also referred to as hematologic tumors, encompass a series of malignant proliferative disorders of the lymphopoietic system, including leukemia, lymphoma, multiple myeloma, and myeloproliferative neoplasms. The dysregulation of inflammatory factors or chronic inflammatory responses plays an indispensable role in the onset and progression of these tumors. The C-X-C motif chemokine receptor (CXCR) serves as a key mediator of immune-inflammatory responses. Through its specific regulatory mechanisms, CXCR is involved in the transduction and activation of various signaling pathways, thereby mediating the malignant biological characteristics of blood tumor cells, such as uncontrolled proliferation, differentiation, invasion, migration, autophagy, and apoptosis. In the bone marrow microenvironment, CXCR plays a pivotal role. This review systematically analyzes and elucidates the roles and mechanisms of the CXCR family in hematologic malignancies, aiming to provide new insights into the biological mechanisms and clinical significance of these diseases. The CXCR family holds great potential as a molecular marker for both fundamental research and the clinical diagnosis and treatment of hematologic malignancies.

Indexed as

Bone MarrowHematologic NeoplasmsReceptors, CXCRTumor MicroenvironmentAnimalsHumansSignal TransductionReceptors, CXCRcarcinogenic mechanismsCXC chemokine receptorhematologic malignancieslymphopoietic systemtherapeutic targets

Identifiers

PMID40427609
PMCPMC12109521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.